AWQ-12620-28286
2 vaccinations
1 coded response
6 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 325 / FL
- Registered
- 2021-03-30
- Relationship
- Self
- Race
- White
- Ethnicity
- Hispanic or Latino
Timeline
-
2021-03-30
Registered in v-safe
-
2021-03-30
Dose 1 — Janssen/Johnson & Johnson
- 2021-03-30
-
2021-04-01
Health check-in — days 1–6 daily, dose 1Feeling: Poor · Site: Pain · Fever · Chills, Headache, Muscle or body aches, Nausea, Vomiting · Be unable to work, Be unable to do your normal daily activitiesAdult check-in
-
2021-04-01
Report sent to call center — days 1–6 daily, dose 1Be unable to work · Be unable to do your normal daily activitiesno matching call case
-
2021-09-30
Survey response — 6 months, dose 1MedDRA: Ageusia, Anosmia, Fatigue, Headache — Feeling: GoodFree text: Headache, tiredness, lost taste and smellMedDRA releases: 2024-11 · check-in free text available
-
2022-01-04
Dose 2 — Janssen/Johnson & JohnsonCo-administered: Flu
- 2022-03-30
- 2022-07-07
- 2023-01-06
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-03-30 | Janssen/Johnson & Johnson | |
| 2 | 2022-01-04 | Janssen/Johnson & Johnson | Flu |
Call center
1 check-in flagged for a call with no call center case on record
Free text
Release 9 — 6 months, dose 1
Symptoms: Headache, tiredness, lost taste and smell
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Ageusia | · | · | ✓ |
| SD | Anosmia | · | · | ✓ |
| SD | Fatigue | · | · | ✓ |
| SD | Headache | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release